nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—FPGS—myometrium—uterine cancer	0.0179	0.0693	CbGeAlD
Pralatrexate—SLC19A1—female reproductive system—uterine cancer	0.0157	0.0607	CbGeAlD
Pralatrexate—FPGS—decidua—uterine cancer	0.0133	0.0514	CbGeAlD
Pralatrexate—Night sweats—Progesterone—uterine cancer	0.0133	0.045	CcSEcCtD
Pralatrexate—FPGS—endometrium—uterine cancer	0.0126	0.0488	CbGeAlD
Pralatrexate—FPGS—mammalian vulva—uterine cancer	0.0122	0.0472	CbGeAlD
Pralatrexate—DHFR—myometrium—uterine cancer	0.0117	0.045	CbGeAlD
Pralatrexate—FPGS—female reproductive system—uterine cancer	0.0105	0.0404	CbGeAlD
Pralatrexate—FPGS—female gonad—uterine cancer	0.00952	0.0368	CbGeAlD
Pralatrexate—FPGS—vagina—uterine cancer	0.00946	0.0366	CbGeAlD
Pralatrexate—SLC19A1—lymph node—uterine cancer	0.00919	0.0355	CbGeAlD
Pralatrexate—TYMS—uterine cervix—uterine cancer	0.00916	0.0354	CbGeAlD
Pralatrexate—DHFR—uterine cervix—uterine cancer	0.00907	0.035	CbGeAlD
Pralatrexate—TYMS—smooth muscle tissue—uterine cancer	0.0089	0.0344	CbGeAlD
Pralatrexate—DHFR—decidua—uterine cancer	0.00864	0.0334	CbGeAlD
Pralatrexate—DHFR—renal system—uterine cancer	0.00848	0.0328	CbGeAlD
Pralatrexate—Neoplasm malignant—Progesterone—uterine cancer	0.00838	0.0284	CcSEcCtD
Pralatrexate—TYMS—endometrium—uterine cancer	0.00828	0.032	CbGeAlD
Pralatrexate—DHFR—endometrium—uterine cancer	0.0082	0.0317	CbGeAlD
Pralatrexate—TYMS—mammalian vulva—uterine cancer	0.00801	0.031	CbGeAlD
Pralatrexate—DHFR—mammalian vulva—uterine cancer	0.00793	0.0307	CbGeAlD
Pralatrexate—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.0076	0.0258	CcSEcCtD
Pralatrexate—DHFR—uterus—uterine cancer	0.00756	0.0292	CbGeAlD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—RRM2—uterine cancer	0.0075	0.0179	CbGpPWpGaD
Pralatrexate—DHFR—Fluoropyrimidine Activity—RRM2—uterine cancer	0.0075	0.0179	CbGpPWpGaD
Pralatrexate—Tumour lysis syndrome—Epirubicin—uterine cancer	0.0074	0.0251	CcSEcCtD
Pralatrexate—TYMS—female reproductive system—uterine cancer	0.00686	0.0265	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—uterine cancer	0.00684	0.0232	CcSEcCtD
Pralatrexate—DHFR—female reproductive system—uterine cancer	0.00679	0.0262	CbGeAlD
Pralatrexate—TYMS—Podofilox—Etoposide—uterine cancer	0.00669	0.531	CbGdCrCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00655	0.0156	CbGpPWpGaD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—RRM2—uterine cancer	0.00655	0.0156	CbGpPWpGaD
Pralatrexate—TYMS—female gonad—uterine cancer	0.00624	0.0241	CbGeAlD
Pralatrexate—TYMS—vagina—uterine cancer	0.00621	0.024	CbGeAlD
Pralatrexate—DHFR—female gonad—uterine cancer	0.00618	0.0239	CbGeAlD
Pralatrexate—DHFR—vagina—uterine cancer	0.00615	0.0237	CbGeAlD
Pralatrexate—SLC19A1—Folate Metabolism—MTHFR—uterine cancer	0.00614	0.0147	CbGpPWpGaD
Pralatrexate—FPGS—lymph node—uterine cancer	0.00612	0.0236	CbGeAlD
Pralatrexate—Sepsis—Medroxyprogesterone Acetate—uterine cancer	0.00563	0.0191	CcSEcCtD
Pralatrexate—Tetrahydrofolic acid—MTHFR—uterine cancer	0.0055	0.373	CrCbGaD
Pralatrexate—Folic Acid—MTHFR—uterine cancer	0.0055	0.373	CrCbGaD
Pralatrexate—Pain in extremity—Progesterone—uterine cancer	0.0052	0.0176	CcSEcCtD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.00492	0.0117	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—CCL2—uterine cancer	0.0048	0.0115	CbGpPWpGaD
Pralatrexate—Liver function test abnormal—Progesterone—uterine cancer	0.0048	0.0163	CcSEcCtD
Pralatrexate—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00471	0.016	CcSEcCtD
Pralatrexate—Sepsis—Dactinomycin—uterine cancer	0.00439	0.0149	CcSEcCtD
Pralatrexate—DHFR—One Carbon Metabolism—MTHFR—uterine cancer	0.00433	0.0103	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Medroxyprogesterone Acetate—uterine cancer	0.00429	0.0145	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—GPX3—uterine cancer	0.00425	0.0101	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MSH6—uterine cancer	0.0042	0.01	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.00418	0.00999	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Progesterone—uterine cancer	0.00417	0.0142	CcSEcCtD
Pralatrexate—TYMS—lymph node—uterine cancer	0.00401	0.0155	CbGeAlD
Pralatrexate—DHFR—E2F transcription factor network—RRM2—uterine cancer	0.00398	0.00949	CbGpPWpGaD
Pralatrexate—DHFR—lymph node—uterine cancer	0.00397	0.0154	CbGeAlD
Pralatrexate—DHFR—Trans-sulfuration and one carbon metabolism—MTHFR—uterine cancer	0.00389	0.00929	CbGpPWpGaD
Pralatrexate—Body temperature increased—Carboplatin—uterine cancer	0.00384	0.013	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.00379	0.00906	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00378	0.0128	CcSEcCtD
Pralatrexate—TYMS—One Carbon Metabolism—MTHFR—uterine cancer	0.00378	0.00902	CbGpPWpGaD
Pralatrexate—Methotrexate—MTHFR—uterine cancer	0.00376	0.255	CrCbGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MSH6—uterine cancer	0.00366	0.00874	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00358	0.00856	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—RRM2—uterine cancer	0.00347	0.00828	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—RRM2—uterine cancer	0.00346	0.00825	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—uterine cancer	0.00345	0.00823	CbGpPWpGaD
Pralatrexate—TYMS—Danazol—Progesterone—uterine cancer	0.00344	0.273	CbGdCrCtD
Pralatrexate—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.00342	0.0116	CcSEcCtD
Pralatrexate—TYMS—Trans-sulfuration and one carbon metabolism—MTHFR—uterine cancer	0.00339	0.0081	CbGpPWpGaD
Pralatrexate—Liver function test abnormal—Dactinomycin—uterine cancer	0.00339	0.0115	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.00331	0.00791	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.00331	0.0112	CcSEcCtD
Pralatrexate—TYMS—Nucleotide metabolism—RRM2—uterine cancer	0.00329	0.00786	CbGpPWpGaD
Pralatrexate—Sepsis—Etoposide—uterine cancer	0.00318	0.0108	CcSEcCtD
Pralatrexate—Back pain—Progesterone—uterine cancer	0.00303	0.0103	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—RRM2—uterine cancer	0.00302	0.0072	CbGpPWpGaD
Pralatrexate—Pancytopenia—Dactinomycin—uterine cancer	0.00301	0.0102	CcSEcCtD
Pralatrexate—Neutropenia—Dactinomycin—uterine cancer	0.00297	0.0101	CcSEcCtD
Pralatrexate—Anaemia—Progesterone—uterine cancer	0.00289	0.00981	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—RRM2—uterine cancer	0.00289	0.00689	CbGpPWpGaD
Pralatrexate—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00274	0.0093	CcSEcCtD
Pralatrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—uterine cancer	0.00273	0.00652	CbGpPWpGaD
Pralatrexate—Cough—Progesterone—uterine cancer	0.00273	0.00926	CcSEcCtD
Pralatrexate—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00889	CcSEcCtD
Pralatrexate—Oedema—Progesterone—uterine cancer	0.00255	0.00866	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—RRM2—uterine cancer	0.00252	0.00601	CbGpPWpGaD
Pralatrexate—Tachycardia—Progesterone—uterine cancer	0.00249	0.00845	CcSEcCtD
Pralatrexate—TYMS—Levonorgestrel—Progesterone—uterine cancer	0.00247	0.196	CbGdCrCtD
Pralatrexate—Anorexia—Progesterone—uterine cancer	0.00243	0.00825	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—RRM2—uterine cancer	0.00243	0.00581	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Epirubicin—uterine cancer	0.0024	0.00815	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.00239	0.00812	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—STAR—uterine cancer	0.00236	0.00563	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—uterine cancer	0.00233	0.00556	CbGpPWpGaD
Pralatrexate—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00785	CcSEcCtD
Pralatrexate—Dyspnoea—Progesterone—uterine cancer	0.00228	0.00772	CcSEcCtD
Pralatrexate—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00227	0.00768	CcSEcCtD
Pralatrexate—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00226	0.00766	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—uterine cancer	0.00222	0.00754	CcSEcCtD
Pralatrexate—Decreased appetite—Progesterone—uterine cancer	0.00222	0.00753	CcSEcCtD
Pralatrexate—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00748	CcSEcCtD
Pralatrexate—Fatigue—Progesterone—uterine cancer	0.0022	0.00747	CcSEcCtD
Pralatrexate—Constipation—Progesterone—uterine cancer	0.00218	0.0074	CcSEcCtD
Pralatrexate—Pancytopenia—Etoposide—uterine cancer	0.00218	0.0074	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—MTHFR—uterine cancer	0.00218	0.0052	CbGpPWpGaD
Pralatrexate—Neutropenia—Etoposide—uterine cancer	0.00215	0.00728	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—RRM2—uterine cancer	0.00212	0.00507	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Progesterone—uterine cancer	0.00209	0.00708	CcSEcCtD
Pralatrexate—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00206	0.007	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—uterine cancer	0.00204	0.00693	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—NDUFB11—uterine cancer	0.00204	0.00487	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SRD5A2—uterine cancer	0.00204	0.00487	CbGpPWpGaD
Pralatrexate—Body temperature increased—Progesterone—uterine cancer	0.00202	0.00685	CcSEcCtD
Pralatrexate—Abdominal pain—Progesterone—uterine cancer	0.00202	0.00685	CcSEcCtD
Pralatrexate—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00201	0.00682	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.002	0.00478	CbGpPWpGaD
Pralatrexate—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.002	0.00677	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—uterine cancer	0.00198	0.00671	CcSEcCtD
Pralatrexate—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00198	0.00671	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—HNF1B—uterine cancer	0.00192	0.00459	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKR1B10—uterine cancer	0.00189	0.00452	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00189	0.00642	CcSEcCtD
Pralatrexate—DHFR—Metabolism of nitric oxide—AKT1—uterine cancer	0.00189	0.00452	CbGpPWpGaD
Pralatrexate—Asthenia—Progesterone—uterine cancer	0.00183	0.00621	CcSEcCtD
Pralatrexate—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00183	0.0062	CcSEcCtD
Pralatrexate—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00183	0.0062	CcSEcCtD
Pralatrexate—Pruritus—Progesterone—uterine cancer	0.00181	0.00613	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—uterine cancer	0.00181	0.00612	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—uterine cancer	0.00178	0.00604	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—uterine cancer	0.00177	0.00599	CcSEcCtD
Pralatrexate—Diarrhoea—Progesterone—uterine cancer	0.00175	0.00592	CcSEcCtD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.00175	0.00417	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NDUFB11—uterine cancer	0.00173	0.00414	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—SRD5A2—uterine cancer	0.00173	0.00414	CbGpPWpGaD
Pralatrexate—Anorexia—Dactinomycin—uterine cancer	0.00172	0.00583	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—CCL2—uterine cancer	0.00171	0.00407	CbGpPWpGaD
Pralatrexate—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.00563	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—uterine cancer	0.00165	0.00559	CcSEcCtD
Pralatrexate—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00555	CcSEcCtD
Pralatrexate—Vomiting—Progesterone—uterine cancer	0.00162	0.00551	CcSEcCtD
Pralatrexate—Rash—Progesterone—uterine cancer	0.00161	0.00546	CcSEcCtD
Pralatrexate—FPGS—Disease—AKR1B10—uterine cancer	0.00161	0.00384	CbGpPWpGaD
Pralatrexate—Dermatitis—Progesterone—uterine cancer	0.00161	0.00545	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—MLH3—uterine cancer	0.00161	0.00384	CbGpPWpGaD
Pralatrexate—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00537	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—uterine cancer	0.00157	0.00532	CcSEcCtD
Pralatrexate—SLC19A1—Disease—RNF43—uterine cancer	0.00157	0.00375	CbGpPWpGaD
Pralatrexate—Fatigue—Dactinomycin—uterine cancer	0.00156	0.00528	CcSEcCtD
Pralatrexate—Back pain—Etoposide—uterine cancer	0.00155	0.00525	CcSEcCtD
Pralatrexate—Nausea—Progesterone—uterine cancer	0.00152	0.00514	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—uterine cancer	0.00149	0.00505	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—uterine cancer	0.00148	0.00502	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00148	0.005	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—STAR—uterine cancer	0.00147	0.00352	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKR1B1—uterine cancer	0.00147	0.00352	CbGpPWpGaD
Pralatrexate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00499	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2B—uterine cancer	0.00147	0.0035	CbGpPWpGaD
Pralatrexate—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00495	CcSEcCtD
Pralatrexate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00494	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—uterine cancer	0.00144	0.00344	CbGpPWpGaD
Pralatrexate—Leukopenia—Etoposide—uterine cancer	0.00143	0.00486	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—uterine cancer	0.00143	0.00484	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—uterine cancer	0.00143	0.00484	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—MLH3—uterine cancer	0.0014	0.00335	CbGpPWpGaD
Pralatrexate—Cough—Etoposide—uterine cancer	0.0014	0.00474	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—uterine cancer	0.00139	0.0047	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—uterine cancer	0.00138	0.00467	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—uterine cancer	0.00138	0.00466	CcSEcCtD
Pralatrexate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.00466	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CDKN2A—uterine cancer	0.00137	0.00327	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Epirubicin—uterine cancer	0.00136	0.0046	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.00134	0.00455	CcSEcCtD
Pralatrexate—FPGS—Disease—RNF43—uterine cancer	0.00133	0.00319	CbGpPWpGaD
Pralatrexate—Asthenia—Dactinomycin—uterine cancer	0.0013	0.00439	CcSEcCtD
Pralatrexate—SLC19A1—Disease—AKR1C1—uterine cancer	0.00129	0.00308	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.00128	0.00307	CbGpPWpGaD
Pralatrexate—Dehydration—Doxorubicin—uterine cancer	0.00128	0.00435	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2B—uterine cancer	0.00128	0.00306	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Etoposide—uterine cancer	0.00128	0.00434	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—uterine cancer	0.00128	0.00432	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—uterine cancer	0.00127	0.00432	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—NDC80—uterine cancer	0.00126	0.003	CbGpPWpGaD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—uterine cancer	0.00126	0.003	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Doxorubicin—uterine cancer	0.00125	0.00425	CcSEcCtD
Pralatrexate—FPGS—Metabolism—STAR—uterine cancer	0.00125	0.00299	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKR1B1—uterine cancer	0.00125	0.00299	CbGpPWpGaD
Pralatrexate—Anorexia—Etoposide—uterine cancer	0.00125	0.00422	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.00124	0.00421	CcSEcCtD
Pralatrexate—Diarrhoea—Dactinomycin—uterine cancer	0.00124	0.00419	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—EZH2—uterine cancer	0.00123	0.00295	CbGpPWpGaD
Pralatrexate—Pancytopenia—Epirubicin—uterine cancer	0.00122	0.00415	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CDKN1B—uterine cancer	0.00121	0.0029	CbGpPWpGaD
Pralatrexate—Neutropenia—Epirubicin—uterine cancer	0.0012	0.00408	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—uterine cancer	0.0012	0.00406	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CDKN2A—uterine cancer	0.0012	0.00286	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.00119	0.00284	CbGpPWpGaD
Pralatrexate—Dyspnoea—Etoposide—uterine cancer	0.00116	0.00395	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—POLD1—uterine cancer	0.00116	0.00276	CbGpPWpGaD
Pralatrexate—Vomiting—Dactinomycin—uterine cancer	0.00115	0.00389	CcSEcCtD
Pralatrexate—Rash—Dactinomycin—uterine cancer	0.00114	0.00386	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—uterine cancer	0.00114	0.00385	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—uterine cancer	0.00113	0.00384	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—uterine cancer	0.00113	0.00382	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—NDC80—uterine cancer	0.00112	0.00269	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—DCN—uterine cancer	0.00112	0.00267	CbGpPWpGaD
Pralatrexate—Constipation—Etoposide—uterine cancer	0.00112	0.00379	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—uterine cancer	0.00111	0.00378	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.00111	0.00375	CcSEcCtD
Pralatrexate—FPGS—Disease—AKR1C1—uterine cancer	0.0011	0.00262	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—NDC80—uterine cancer	0.0011	0.00262	CbGpPWpGaD
Pralatrexate—Epistaxis—Epirubicin—uterine cancer	0.00108	0.00367	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—AKR1C1—uterine cancer	0.00108	0.00258	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.00108	0.00258	CbGpPWpGaD
Pralatrexate—Nausea—Dactinomycin—uterine cancer	0.00107	0.00364	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—POLD1—uterine cancer	0.00107	0.00255	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Etoposide—uterine cancer	0.00107	0.00362	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—EP300—uterine cancer	0.00107	0.00255	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—CDKN1B—uterine cancer	0.00106	0.00253	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	0.00106	0.00252	CbGpPWpGaD
Pralatrexate—Body temperature increased—Etoposide—uterine cancer	0.00103	0.0035	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—uterine cancer	0.00103	0.0035	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—uterine cancer	0.001	0.0034	CcSEcCtD
Pralatrexate—SLC19A1—Disease—AKR1C3—uterine cancer	0.000995	0.00237	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—POLD1—uterine cancer	0.000984	0.00235	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—NDC80—uterine cancer	0.000981	0.00234	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.00097	0.00231	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HMGA1—uterine cancer	0.000969	0.00231	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—RRM2—uterine cancer	0.000964	0.0023	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—POLD1—uterine cancer	0.000956	0.00228	CbGpPWpGaD
Pralatrexate—FPGS—Disease—DCN—uterine cancer	0.000951	0.00227	CbGpPWpGaD
Pralatrexate—Asthenia—Etoposide—uterine cancer	0.000937	0.00318	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—DCN—uterine cancer	0.000936	0.00224	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000933	0.00223	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—EP300—uterine cancer	0.000931	0.00222	CbGpPWpGaD
Pralatrexate—Pruritus—Etoposide—uterine cancer	0.000924	0.00313	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	0.000921	0.0022	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKR1C1—uterine cancer	0.00092	0.0022	CbGpPWpGaD
Pralatrexate—Diarrhoea—Etoposide—uterine cancer	0.000894	0.00303	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000892	0.00213	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—FBXW7—uterine cancer	0.000887	0.00212	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP11A1—uterine cancer	0.000882	0.00211	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—CDKN1B—uterine cancer	0.000881	0.0021	CbGpPWpGaD
Pralatrexate—Back pain—Epirubicin—uterine cancer	0.000868	0.00294	CcSEcCtD
Pralatrexate—FPGS—Disease—AKR1C3—uterine cancer	0.000846	0.00202	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	0.000839	0.002	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—POLD1—uterine cancer	0.000835	0.00199	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKR1C3—uterine cancer	0.000833	0.00199	CbGpPWpGaD
Pralatrexate—Vomiting—Etoposide—uterine cancer	0.000831	0.00282	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—uterine cancer	0.000829	0.00281	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—uterine cancer	0.000827	0.00198	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HMGA1—uterine cancer	0.000824	0.00197	CbGpPWpGaD
Pralatrexate—Rash—Etoposide—uterine cancer	0.000824	0.00279	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—uterine cancer	0.000823	0.00279	CcSEcCtD
Pralatrexate—FPGS—Metabolism—RRM2—uterine cancer	0.00082	0.00196	CbGpPWpGaD
Pralatrexate—Leukopenia—Epirubicin—uterine cancer	0.000803	0.00272	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—uterine cancer	0.000803	0.00272	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—RRM2—uterine cancer	0.000797	0.0019	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—DCN—uterine cancer	0.000796	0.0019	CbGpPWpGaD
Pralatrexate—Cough—Epirubicin—uterine cancer	0.000783	0.00265	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000778	0.00186	CbGpPWpGaD
Pralatrexate—Nausea—Etoposide—uterine cancer	0.000776	0.00263	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—CDKN1B—uterine cancer	0.000769	0.00184	CbGpPWpGaD
Pralatrexate—Anaemia—Doxorubicin—uterine cancer	0.000767	0.0026	CcSEcCtD
Pralatrexate—FPGS—Disease—FBXW7—uterine cancer	0.000754	0.0018	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP11A1—uterine cancer	0.00075	0.00179	CbGpPWpGaD
Pralatrexate—Leukopenia—Doxorubicin—uterine cancer	0.000743	0.00252	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	0.000743	0.00177	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—uterine cancer	0.000732	0.00248	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	0.000732	0.00175	CbGpPWpGaD
Pralatrexate—Cough—Doxorubicin—uterine cancer	0.000725	0.00246	CcSEcCtD
Pralatrexate—DHFR—Metabolism—NDUFB11—uterine cancer	0.000724	0.00173	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SRD5A2—uterine cancer	0.000724	0.00173	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000722	0.00172	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Epirubicin—uterine cancer	0.000717	0.00243	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.000716	0.00171	CbGpPWpGaD
Pralatrexate—Tachycardia—Epirubicin—uterine cancer	0.000715	0.00242	CcSEcCtD
Pralatrexate—FPGS—Metabolism—AKR1C3—uterine cancer	0.000708	0.00169	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MLH1—uterine cancer	0.000708	0.00169	CbGpPWpGaD
Pralatrexate—Anorexia—Epirubicin—uterine cancer	0.000698	0.00237	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—RRM2—uterine cancer	0.000696	0.00166	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN2B—uterine cancer	0.000695	0.00166	CbGpPWpGaD
Pralatrexate—Oedema—Doxorubicin—uterine cancer	0.000678	0.0023	CcSEcCtD
Pralatrexate—DHFR—Disease—AKR1B10—uterine cancer	0.000673	0.00161	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—uterine cancer	0.000663	0.00225	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	0.000663	0.00158	CbGpPWpGaD
Pralatrexate—Tachycardia—Doxorubicin—uterine cancer	0.000661	0.00224	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—uterine cancer	0.000653	0.00221	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—STK11—uterine cancer	0.000649	0.00155	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP19A1—uterine cancer	0.000649	0.00155	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	0.000648	0.00155	CbGpPWpGaD
Pralatrexate—Anorexia—Doxorubicin—uterine cancer	0.000646	0.00219	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—YWHAE—uterine cancer	0.00064	0.00153	CbGpPWpGaD
Pralatrexate—Decreased appetite—Epirubicin—uterine cancer	0.000637	0.00216	CcSEcCtD
Pralatrexate—SLC19A1—Disease—SMAD3—uterine cancer	0.000634	0.00151	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SRD5A2—uterine cancer	0.000632	0.00151	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NDUFB11—uterine cancer	0.000632	0.00151	CbGpPWpGaD
Pralatrexate—Fatigue—Epirubicin—uterine cancer	0.000631	0.00214	CcSEcCtD
Pralatrexate—Constipation—Epirubicin—uterine cancer	0.000626	0.00212	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.000625	0.00149	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MLH1—uterine cancer	0.000618	0.00147	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—FGFR2—uterine cancer	0.000605	0.00144	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—uterine cancer	0.000604	0.00205	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000599	0.00203	CcSEcCtD
Pralatrexate—FPGS—Disease—CDKN2B—uterine cancer	0.000591	0.00141	CbGpPWpGaD
Pralatrexate—Decreased appetite—Doxorubicin—uterine cancer	0.000589	0.002	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—uterine cancer	0.000584	0.00198	CcSEcCtD
Pralatrexate—SLC19A1—Disease—MTHFR—uterine cancer	0.000582	0.00139	CbGpPWpGaD
Pralatrexate—Constipation—Doxorubicin—uterine cancer	0.000579	0.00196	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—uterine cancer	0.000579	0.00196	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—uterine cancer	0.000579	0.00196	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	0.000579	0.00138	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—YWHAE—uterine cancer	0.000559	0.00133	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RNF43—uterine cancer	0.000557	0.00133	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000554	0.00188	CcSEcCtD
Pralatrexate—FPGS—Metabolism—CYP19A1—uterine cancer	0.000552	0.00132	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—STK11—uterine cancer	0.000552	0.00132	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SMAD3—uterine cancer	0.000539	0.00129	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000538	0.00128	CbGpPWpGaD
Pralatrexate—Body temperature increased—Doxorubicin—uterine cancer	0.000536	0.00182	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—uterine cancer	0.000536	0.00182	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.00053	0.00127	CbGpPWpGaD
Pralatrexate—Asthenia—Epirubicin—uterine cancer	0.000525	0.00178	CcSEcCtD
Pralatrexate—DHFR—Metabolism—STAR—uterine cancer	0.000524	0.00125	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKR1B1—uterine cancer	0.000524	0.00125	CbGpPWpGaD
Pralatrexate—Pruritus—Epirubicin—uterine cancer	0.000518	0.00176	CcSEcCtD
Pralatrexate—FPGS—Disease—FGFR2—uterine cancer	0.000514	0.00123	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—uterine cancer	0.000501	0.0017	CcSEcCtD
Pralatrexate—FPGS—Disease—MTHFR—uterine cancer	0.000495	0.00118	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000491	0.00117	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—MTHFR—uterine cancer	0.000488	0.00116	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—uterine cancer	0.000486	0.00165	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—CDKN2B—uterine cancer	0.000481	0.00115	CbGpPWpGaD
Pralatrexate—Pruritus—Doxorubicin—uterine cancer	0.000479	0.00163	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000469	0.00112	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—uterine cancer	0.000466	0.00158	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.000464	0.00111	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000464	0.00111	CbGpPWpGaD
Pralatrexate—Diarrhoea—Doxorubicin—uterine cancer	0.000464	0.00157	CcSEcCtD
Pralatrexate—Rash—Epirubicin—uterine cancer	0.000462	0.00157	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—uterine cancer	0.000461	0.00156	CcSEcCtD
Pralatrexate—DHFR—Disease—AKR1C1—uterine cancer	0.000459	0.0011	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—STAR—uterine cancer	0.000457	0.00109	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKR1B1—uterine cancer	0.000457	0.00109	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000452	0.00108	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—uterine cancer	0.000435	0.00147	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—PTEN—uterine cancer	0.000434	0.00104	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000431	0.00103	CbGpPWpGaD
Pralatrexate—Vomiting—Doxorubicin—uterine cancer	0.000431	0.00146	CcSEcCtD
Pralatrexate—Rash—Doxorubicin—uterine cancer	0.000427	0.00145	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—uterine cancer	0.000427	0.00145	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—CDKN2B—uterine cancer	0.00042	0.001	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BIRC5—uterine cancer	0.000415	0.000991	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—MTHFR—uterine cancer	0.000415	0.00099	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—EP300—uterine cancer	0.000414	0.000988	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—POLD1—uterine cancer	0.000411	0.000981	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000408	0.000975	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.000405	0.000967	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—uterine cancer	0.000403	0.00136	CcSEcCtD
Pralatrexate—DHFR—Disease—DCN—uterine cancer	0.000397	0.000948	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKR1C1—uterine cancer	0.000384	0.000918	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—uterine cancer	0.00038	0.000907	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BIRC5—uterine cancer	0.000362	0.000865	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—POLD1—uterine cancer	0.000359	0.000856	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKR1C3—uterine cancer	0.000353	0.000844	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1B—uterine cancer	0.000352	0.00084	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000347	0.000829	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HMGA1—uterine cancer	0.000344	0.000822	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—RRM2—uterine cancer	0.000343	0.000818	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKR1C1—uterine cancer	0.000335	0.000801	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—DCN—uterine cancer	0.000333	0.000794	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—uterine cancer	0.000332	0.000794	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—uterine cancer	0.000324	0.000773	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—uterine cancer	0.000323	0.000771	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000319	0.000762	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FBXW7—uterine cancer	0.000315	0.000752	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP11A1—uterine cancer	0.000313	0.000748	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EP300—uterine cancer	0.000309	0.000738	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000309	0.000737	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.000308	0.000734	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1B—uterine cancer	0.000299	0.000714	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—RRM2—uterine cancer	0.000299	0.000714	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—uterine cancer	0.000296	0.000707	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKR1C3—uterine cancer	0.000296	0.000706	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—DCN—uterine cancer	0.00029	0.000693	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—uterine cancer	0.000289	0.00069	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—uterine cancer	0.000283	0.000675	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—uterine cancer	0.000275	0.000658	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—uterine cancer	0.000275	0.000657	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP11A1—uterine cancer	0.000273	0.000653	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—uterine cancer	0.000272	0.00065	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—uterine cancer	0.000271	0.000648	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.000268	0.000641	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EP300—uterine cancer	0.000263	0.000627	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000261	0.000622	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—EP300—uterine cancer	0.000259	0.000618	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKR1C3—uterine cancer	0.000258	0.000616	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—uterine cancer	0.000249	0.000594	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN2B—uterine cancer	0.000247	0.000589	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—uterine cancer	0.000246	0.000587	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1B—uterine cancer	0.000244	0.000582	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—uterine cancer	0.00024	0.000573	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—EP300—uterine cancer	0.000239	0.000571	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1B—uterine cancer	0.000238	0.000568	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—uterine cancer	0.000231	0.000551	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—STK11—uterine cancer	0.000231	0.00055	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP19A1—uterine cancer	0.000231	0.00055	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—uterine cancer	0.000229	0.000546	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SMAD3—uterine cancer	0.000225	0.000538	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—EP300—uterine cancer	0.00022	0.000525	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGFR2—uterine cancer	0.000215	0.000513	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—EP300—uterine cancer	0.000214	0.000511	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1B—uterine cancer	0.000213	0.000507	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—uterine cancer	0.000212	0.000505	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—uterine cancer	0.000211	0.000505	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—EP300—uterine cancer	0.000209	0.000498	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MTHFR—uterine cancer	0.000207	0.000494	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—STK11—uterine cancer	0.000201	0.00048	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP19A1—uterine cancer	0.000201	0.00048	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—uterine cancer	0.000194	0.000464	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—uterine cancer	0.000191	0.000457	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—uterine cancer	0.000187	0.000446	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—EP300—uterine cancer	0.000187	0.000446	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—uterine cancer	0.00018	0.000429	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—MTHFR—uterine cancer	0.000173	0.000414	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—uterine cancer	0.000163	0.000389	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—uterine cancer	0.000159	0.000379	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—uterine cancer	0.000156	0.000373	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—uterine cancer	0.000153	0.000365	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—MTHFR—uterine cancer	0.000151	0.000361	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—uterine cancer	0.000135	0.000322	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—uterine cancer	0.000134	0.000319	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—uterine cancer	0.000133	0.000317	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1B—uterine cancer	0.000125	0.000298	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—uterine cancer	0.000118	0.000282	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—uterine cancer	0.000115	0.000275	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EP300—uterine cancer	0.00011	0.000262	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—uterine cancer	0.000103	0.000245	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—uterine cancer	9.64e-05	0.00023	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—EP300—uterine cancer	9.19e-05	0.000219	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—uterine cancer	8.84e-05	0.000211	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—uterine cancer	8.41e-05	0.000201	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—uterine cancer	8.12e-05	0.000194	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—EP300—uterine cancer	8.02e-05	0.000191	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—uterine cancer	7.51e-05	0.000179	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—uterine cancer	6.8e-05	0.000162	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—uterine cancer	6.63e-05	0.000158	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—uterine cancer	5.93e-05	0.000142	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—uterine cancer	5.55e-05	0.000133	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—uterine cancer	4.85e-05	0.000116	CbGpPWpGaD
